Maria Jesús Vidal

Publicaciones destacadas

• Sentinel node after NeoAdjuvancy in node-positive breast cancer. SANA multicentric study

  Autores:

  Rosello IV; Vidal-Sicart S; Sánchez N; Algarra XC; Torras I;

  (...)

  Muñoz M; Prat A; Farre BG; Marsical A; Vargas IA.

  Ver listado completo de autores

  Referencia: European Journal Of Cancer 2020.

• Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

  Autores:

  Cortes, Javier; Dieras, Veronique; Lorenzen, Sylvie; Montemurro, Filippo; Riera-Knorrenschild, Jorge;

  (...)

  Vidal, Maria; Irahara, Natsumi; Wohlfarth, Christine; Aout, Mounir; Gelmon, Karen.

  Ver listado completo de autores

  Referencia: Jama Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Autores:

  Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;

  (...)

  Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.

  Ver listado completo de autores

  Referencia: Breast Cancer Research 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autores:

  Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

  (...)

  Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

  Ver listado completo de autores

  Referencia: Cancer Treatment Reviews 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Autores:

  Braso-Maristany, Fara; Griguolo, Gaia; Pascual, Tomas; Pare, Laia; Nuciforo, Paolo;

  (...)

  Gomis, Roger R; Villagrasa, Patricia; Cortes, Javier; Ciruelos, Eva; Prat, Aleix.

  Ver listado completo de autores

  Referencia: Nature Communications 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Autores:

  Prat, A; Pascual, T; Paré, L; Adamo, B; Brasó-Maristany, F;

  (...)

  Parker, JS; Dieci, MV; Griguolo, G; Conte, P; Guarneri, V.

  Ver listado completo de autores

  Referencia: Journal Of The National Cancer Institute 2020.

• PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

  Autores:

  Prat, A; Tsai, Y -H; Pascual, T; Pare, L; Vidal, M;

  Adamo, B; Brase, J C; Johnston, S R D; Ciruelos, E M; Parker, J S.

  Referencia: Annals Of Oncology 2019.